Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials
- PMID: 17919229
- PMCID: PMC2156150
- DOI: 10.1111/j.1478-3231.2007.01580.x
Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials
Abstract
Aims: To compare interferon monotherapy with its combination with lamivudine for hepatitis B e antigen (HBeAg)-positive hepatitis B treatment.
Methods: Two independent researchers identified pertinent randomized controlled trials. The trials were evaluated for methodological quality and heterogeneity. Rates of sustained virological and biochemical responses, and HBeAg clearance and seroconversion were used as primary efficacy measures. Quantitative meta-analyses were conducted to assess differences between groups for conventional and pegylated interferon, and overall.
Results: Greater sustained virological, biochemical and seroconversion rates were observed with addition of lamivudine to conventional [odds ratio (OR)=3.1, 95% confidence intervals (CI) (1.7-5.5), P<0.0001, OR=1.8, 95% CI (1.2-2.7), P=0.007 and OR=1.8, 95% CI (1.1-2.8), P=0.01 respectively], although not pegylated [OR=1.1, 95% CI (0.5-2.3), P=0.8, OR=1.0, 95% CI (0.7-1.3), P=0.94, and OR=0.9, 95% CI (0.6-1.2), P=0.34 respectively] interferon-alpha, with no significant affect on HBeAg clearance rates [OR=1.6, 95% CI (0.9-2.7), P=0.09, and OR=0.8, 95% CI (0.6-1.1), P=0.26 respectively]. Excluding virological response (P<0.001), pegylated interferon monotherapy and conventional interferon and lamivudine combination therapy were similarly efficacious (P>0.05), with the former studied in harder to treat patients, as evidenced by the superior virological response observed with conventional as compared with pegylated interferon monotherapy (P<0.0001).
Conclusion: In comparable populations, pegylated interferon monotherapy is likely to be equally or more efficacious than conventional interferon and lamivudine combination therapy, thus constituting the treatment of choice, with no added benefit with lamivudine addition. However, when conventional interferon is used, its combination with lamivudine should be considered.
Figures
Similar articles
-
Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials.Adv Ther. 2007 Jul-Aug;24(4):784-95. doi: 10.1007/BF02849971. Adv Ther. 2007. PMID: 17901027
-
Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.Hepatobiliary Pancreat Dis Int. 2010 Oct;9(5):462-72. Hepatobiliary Pancreat Dis Int. 2010. PMID: 20943454
-
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.Ann Intern Med. 2005 Feb 15;142(4):240-50. doi: 10.7326/0003-4819-142-4-200502150-00006. Ann Intern Med. 2005. PMID: 15710957 Clinical Trial.
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047 Review.
-
Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.J Viral Hepat. 2016 Mar;23(3):154-69. doi: 10.1111/jvh.12418. Epub 2015 May 13. J Viral Hepat. 2016. PMID: 25967226 Review.
Cited by
-
Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.Pharmaceuticals (Basel). 2016 Dec 16;9(4):78. doi: 10.3390/ph9040078. Pharmaceuticals (Basel). 2016. PMID: 27999271 Free PMC article. Review.
-
A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.Int J Environ Res Public Health. 2016 Jul 21;13(5):730. doi: 10.3390/ijerph13070730. Int J Environ Res Public Health. 2016. PMID: 27455288 Free PMC article.
-
Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.J Virol. 2013 Jan;87(1):137-47. doi: 10.1128/JVI.01710-12. Epub 2012 Oct 10. J Virol. 2013. PMID: 23055569 Free PMC article.
-
Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.Drugs Aging. 2008;25(10):823-40. doi: 10.2165/00002512-200825100-00002. Drugs Aging. 2008. PMID: 18808207 Review.
References
-
- Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med. 2005;118:1413. - PubMed
-
- Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet. 2003;362:2089–94. - PubMed
-
- Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med. 2004;350:1118–29. - PubMed
-
- Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J. 2006;36:100–13. - PubMed
-
- Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol. 2006;101(Suppl. 1):S13–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical